Inmagene of Shanghai Partners Affibody’s Novel Immunotherapy Candidate

中国创响生物和瑞典Affibody达成创新免疫疗法药物合作
Published on: May 14, 2020
Author: Amy Liu

Inmagene Biopharma of Shanghai acquired greater China rights to a bispecific molecule aimed at Interleukin-17A (IL-17) for multiple autoimmune diseases from Sweden’s Affibody AB. ABY-035 is currently undergoing a German Phase II trial in patients with psoriasis, where it has shown clear clinical benefits and a good safety profile. Inmagene will be responsible for commercialization in Greater China and South Korea along with development activities in Asia Pacific region, excluding Japan.

Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science Medical Device Pharmaceutical